Cancers | Free Full-Text | New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches
3.1. Young and Fit Patients
3.3. Older and Frail Patients
IDH1 inhibitors have gained approval as a standalone treatment for relapsed or refractory (R/R) IDH1-mutated AML and newly diagnosed AML poor candidates for intensive chemotherapy. Based on the phase III AGILE trial, the FDA has approved the combination of ivosidenib and azacitidine specifically for newly diagnosed IDH1-mutated patients aged 75 and above or those with comorbidities.
Glasdegib, classified as a hedgehog pathway inhibitor, targets an overexpressed pathway in myeloid leukemia cells. Building on this discovery, a clinical evaluation was conducted to evaluate glasdegib in combination with low-dose cytarabine (LDAC) compared to LDAC alone. The study focused on patients over 75 years old who were newly diagnosed with AML and were not suitable for intensive treatment because of age or significant comorbidities.
3.5. Relapsed/Refractory Disease
3.6. Investigational Therapies
AML remains a diagnosis marked by uncertain outcomes, occasionally yielding unsatisfactory results. Numerous trials have explored targeted therapies and immunotherapies as potential treatments for AML. Some of these trials have exhibited promising results, extending hope even for patients with TP53-mutated AML or AML with MLL rearrangements.
3.7. Allogeneic Bone Marrow Transplant
Disasters Expo USA, is proud to be supported by Inergency for their next upcoming edition on March 6th & 7th 2024!
The leading event mitigating the world’s most costly disasters is returning to the Miami Beach
And in case you missed it, here is our ultimate road trip playlist is the perfect mix of podcasts, and hidden gems that will keep you energized for the entire journey-